Consensus Fulgent Genetics, Inc.

Equities

FLGT

US3596641098

Market Closed - Nasdaq Other stock markets 01:30:00 30/04/2024 am IST			5-day change	1st Jan Change
20.58 ^USD	+2.39%		+0.10%	-28.81%

06/03	Piper Sandler Adjusts Price Target on Fulgent Genetics to $25 From $28, Maintains Neutral Rating	MT
29/02	UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating	MT

Evolution of the average Target Price on Fulgent Genetics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

08d743660271c94c94257d5c771a.G0rygcxm7SqHBKHKUqdWFeGOE6FwFEj4NEAQ2t8N_Xg.fg-Cy5VRiWb9QJS9GtFkfZL5XMkvbRyoYwYi76VEl0FILYe3qQKHUtB1xg~156e1f35aa08455d70655c2d749dd8eb

Analyst Recommendations on Fulgent Genetics, Inc.

Piper Sandler Adjusts Price Target on Fulgent Genetics to $25 From $28, Maintains Neutral Rating	06/03	MT
UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating	29/02	MT
UBS Initiates Coverage on Fulgent Genetics With Neutral Rating, $35 Price Target	07/12	MT
Fulgent Genetics Swings to Loss in Q2, Revenue Declines; Raises Guidance; Shares Surge 10% Pre-Bell	04/23/04	MT
Credit Suisse Lowers Fulgent Genetics' Price Target to $45 From $50 After Mixed Q4 Results, Keeps Outperform Rating	02/23/02	MT
Piper Sandler Downgrades Fulgent Genetics to Neutral From Overweight, Adjusts Price Target to $40 From $65	08/22/08	MT
Raymond James Starts Fulgent Genetics at Outperform With $45 Price Target	18/22/18	MT
Piper Sandler Adjusts Price Target on Fulgent Genetics to $65 From $70, Maintains Overweight Rating	14/22/14	MT
Credit Suisse Adjusts Fulgent Genetics' Price Target to $50 From $65, Keeps Outperform Rating	14/22/14	MT
Credit Suisse Initiates Fulgent Genetics at Outperform with $65 Price Target	25/22/25	MT
Piper Sandler Adjusts Fulgent Genetics' Price Target to $70 From $85, Reiterates Overweight Rating	16/22/16	MT
Oppenheimer Adjusts Fulgent Genetics Price Target to $112 From $123, Maintains Outperform Rating	04/22/04	MT
Piper Sandler Adjusts Fulgent Genetics' Price Target to $85 From $80, Reiterates Overweight Rating	01/22/01	MT
Oppenheimer Adjusts Fulgent Genetics Price Target to $123 From $125, Maintains Outperform Rating	24/22/24	MT
Piper Sandler Assumes Fulgent Genetics at Overweight with $80 Price Target	04/22/04	MT
Oppenheimer Adjusts Fulgent Genetics' Price Target to $125 From $141, Maintains Outperform Rating	25/22/25	MT
FULGENT GENETICS : Credit Suisse Adjusts Fulgent Genetics' Price Target to $65 from $55, Keeps Underperform Rating	10/21/10	MT
FULGENT GENETICS : Oppenheimer Adjusts Fulgent Genetics PT to $141 From $118, Maintains Outperform Rating	10/21/10	MT
FULGENT GENETICS : Oppenheimer Adjusts Fulgent Genetics PT to $118 From $126, Maintains Outperform Rating	07/21/07	MT
FULGENT GENETICS : Oppenheimer Adjusts Fulgent Genetics PT to $126 From $130 on Q1 Preview, Maintains Outperform Rating	07/21/07	MT
FULGENT GENETICS : Piper Sandler Adjusts Price Target on Fulgent Genetics to $140 From $135, Maintains Overweight Rating	05/21/05	MT
FULGENT GENETICS : Credit Suisse Raises Fulgent Genetics' Price Target to $49 from $40 on Upbeat Q4 2020 Earnings, Keeps Underperform Rating	05/21/05	MT
FULGENT GENETICS : Oppenheimer Adjusts Fulgent Genetics' Price Target to $130 From $75, Maintains Outperform Rating	01/21/01	MT
FULGENT GENETICS : Credit Suisse Downgrades Fulgent Genetics' Price Target to Underperform From Neutral	08/21/08	MT
FULGENT GENETICS : BTIG Downgrades Fulgent Genetics to Neutral From Buy	24/20/24	MT